1. Home
  2. SLXN vs GNLN Comparison

SLXN vs GNLN Comparison

Compare SLXN & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • GNLN
  • Stock Information
  • Founded
  • SLXN 2008
  • GNLN 2005
  • Country
  • SLXN Israel
  • GNLN United States
  • Employees
  • SLXN N/A
  • GNLN N/A
  • Industry
  • SLXN
  • GNLN Durable Goods
  • Sector
  • SLXN
  • GNLN Consumer Discretionary
  • Exchange
  • SLXN NYSE
  • GNLN Nasdaq
  • Market Cap
  • SLXN 6.9M
  • GNLN 5.8M
  • IPO Year
  • SLXN N/A
  • GNLN 2019
  • Fundamental
  • Price
  • SLXN $0.95
  • GNLN $0.01
  • Analyst Decision
  • SLXN Strong Buy
  • GNLN
  • Analyst Count
  • SLXN 1
  • GNLN 0
  • Target Price
  • SLXN $5.00
  • GNLN N/A
  • AVG Volume (30 Days)
  • SLXN 1.2M
  • GNLN 290.1M
  • Earning Date
  • SLXN 05-13-2025
  • GNLN 05-15-2025
  • Dividend Yield
  • SLXN N/A
  • GNLN N/A
  • EPS Growth
  • SLXN N/A
  • GNLN N/A
  • EPS
  • SLXN N/A
  • GNLN N/A
  • Revenue
  • SLXN N/A
  • GNLN $9,818,000.00
  • Revenue This Year
  • SLXN N/A
  • GNLN $1,541.21
  • Revenue Next Year
  • SLXN N/A
  • GNLN N/A
  • P/E Ratio
  • SLXN N/A
  • GNLN N/A
  • Revenue Growth
  • SLXN N/A
  • GNLN N/A
  • 52 Week Low
  • SLXN $0.58
  • GNLN $0.01
  • 52 Week High
  • SLXN $41.85
  • GNLN $21.80
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • GNLN 20.26
  • Support Level
  • SLXN N/A
  • GNLN $0.01
  • Resistance Level
  • SLXN N/A
  • GNLN $0.01
  • Average True Range (ATR)
  • SLXN 0.00
  • GNLN 0.00
  • MACD
  • SLXN 0.00
  • GNLN 0.01
  • Stochastic Oscillator
  • SLXN 0.00
  • GNLN 20.00

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: